| Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. | |
| | |
MedLine Citation:
|
PMID: 16320723 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Glatiramer acetate (GA) is a disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS) with several putative mechanisms of action. Currently, there is paucity of in vivo human data linking the well-established peripheral immunologic effects of therapy with GA to its potential effects inside the central nervous system (CNS). Brain proton magnetic resonance spectroscopy (MRS) allows in vivo examination of axonal integrity by quantifying the resonance intensity of the neuronal marker N-acetylaspartate (NAA). In a pilot study to investigate the effect of GA on axonal injury, we performed combined brain magnetic resonance imaging (MRI) and MRS studies in 18 treatment na?ve RRMS patients initiating therapy with GA at baseline and annually for two years on therapy. A small group of four treatment na?ve RRMS patients, electing to remain untreated, served as controls. NAA/Cr was measured in a large central brain volume of interest (VOI) as well as the normal appearing white matter (NAWM) within the VOI. After two years, NAA/Cr in the GA-treated group increased significantly by 10.7% in the VOI (2.17 +/- 0.26 versus 1.96 +/- 0.24, P = 0.03) and by 71% in the NAWM (2.23 +/- 0.26 versus 2.08 +/- 0.31, P = 0.04). In the untreated group, NAA/Cr decreased by 8.9% at two years in the VOI (2.01 +/- 0.16 versus 1.83 +/- 0.21, P = 0.03) and 8.2% in the NAWM (2.07 +/- 0.24 versus 1.90 +/- 0.29, P = 0.03). Our data shows that treatment with GA leads to axonal metabolic recovery and protection from sub-lethal axonal injury. These results support an in situ effect of GA therapy inside the CNS and suggest potential neuroprotective effects of GA. |
| | |
Authors:
|
Omar Khan; Yimin Shen; Christina Caon; Fen Bao; Wendy Ching; Melissa Reznar; Alyssa Buccheister; Jiani Hu; Zahid Latif; Alexandros Tselis; Robert Lisak |
Related Documents
:
|
19194883 - Brain metabolism in rett syndrome: age, clinical, and genotype correlations. 15891493 - Radiation-induced brain metabolic changes in the acute and early delayed phase detected... 18516533 - Hepatic angiomyolipoma: a retrospective study of 25 cases. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Multiple sclerosis (Houndmills, Basingstoke, England) Volume: 11 ISSN: 1352-4585 ISO Abbreviation: Mult. Scler. Publication Date: 2005 Dec |
Date Detail:
|
Created Date: 2005-12-02 Completed Date: 2006-02-03 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9509185 Medline TA: Mult Scler Country: England |
Other Details:
|
Languages: eng Pagination: 646-51 Citation Subset: IM |
Affiliation:
|
Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, MI 48201, USA. okhan@med.wayne.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aspartic Acid / analogs & derivatives, metabolism Axons / metabolism, pathology Creatine / metabolism Female Humans Immunosuppressive Agents / administration & dosage* Magnetic Resonance Imaging Magnetic Resonance Spectroscopy* Male Middle Aged Multiple Sclerosis, Relapsing-Remitting / drug therapy*, metabolism*, pathology Neuroprotective Agents / administration & dosage Peptides / administration & dosage* Pilot Projects Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Immunosuppressive Agents; 0/Neuroprotective Agents; 0/Peptides; 0/copolymer 1; 56-84-8/Aspartic Acid; 57-00-1/Creatine; 997-55-7/N-acetylaspartate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis.
Next Document: Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate.